The big question
Many guidelines have used one starting age for breast cancer screening. But in the US, Black women die of breast cancer at higher rates, especially at younger ages. The researchers asked whether starting ages should reflect these differences.
What they did
The team looked at all 415,277 breast cancer deaths among US female patients from 2011 to 2020. They calculated each group's chance of dying of breast cancer over the next 10 years at each age. Then they found the age at which each racial and ethnic group reached the same risk level as a typical 50-year-old.
What they found
Among women in their 40s, there were 27 breast cancer deaths per 100,000 people each year for Black women, compared with 15 for White women. Black women reached the age-50 risk level 8 years earlier, at age 42. White women reached it at 51, American Indian or Alaska Native and Hispanic women at 57, and Asian or Pacific Islander women at 61.
Why it matters
The study puts a number on a real gap. It suggests that earlier screening for Black women could help address deaths from breast cancer that starts at younger ages.
What it doesn't mean
This study used death records, where race was reported by others; it was not a trial of screening. The later ages for some groups are a statistical result, not advice to wait. Guidelines change over time; this study used the age-50 starting point US guidelines recommended when it was written.
Read the original abstract+
Importance: Breast cancer (BC) is the second leading cause of cancer death in women, and there is a substantial disparity in BC mortality by race, especially for early-onset BC in Black women. Many guidelines recommend starting BC screening from age 50 years; however, the current one-size-fits-all policy to start screening all women from a certain age may not be fair, equitable, or optimal. Objective: To provide race and ethnicity-adapted starting ages of BC screening based on data on current racial and ethnic disparities in BC mortality. Design, Setting, and Participants: This nationwide population-based cross-sectional study was conducted using data on BC mortality in female patients in the US who died of BC in 2011 to 2020. Exposures: Proxy-reported race and ethnicity information was used. The risk-adapted starting age of BC screening by race and ethnicity was measured based on 10-year cumulative risk of BC-specific death. Age-specific 10-year cumulative risk was calculated based on age group-specific mortality data without modeling or adjustment. Main Outcomes and Measures: Disease-specific mortality due to invasive BC in female patients. Results: There were BC-specific deaths among 415 277 female patients (1880 American Indian or Alaska Native [0.5%], 12 086 Asian or Pacific Islander [2.9%], 62 695 Black [15.1%], 28 747 Hispanic [6.9%], and 309 869 White [74.6%]; 115 214 patients died before age 60 years [27.7%]) of any age in the US in 2011 to 2020. BC mortality per 100 000 person-years for ages 40 to 49 years was 27 deaths in Black females, 15 deaths in White females, and 11 deaths in American Indian or Alaska Native, Hispanic, and Asian or Pacific Islander females. When BC screening was recommended to start at age 50 years for all females with a 10-year cumulative risk of BC death of 0.329%, Black females reached this risk threshold level 8 years earlier, at age 42 years, whereas White females reached it at age 51 years, American Indian or Alaska Native and Hispanic females at age 57 years, and Asian or Pacific Islander females 11 years later, at age 61 years. Race and ethnicity-adapted starting ages for Black females were 6 years earlier for mass screening at age 40 years and 7 years earlier for mass screening at age 45 years. Conclusions and Relevance: This study provides evidence-based race-adapted starting ages for BC screening. These findings suggest that health policy makers may consider a risk-adapted approach to BC screening in which individuals who are at high risk are screened earlier to address mortality due to early-onset BC before the recommended age of mass screening.
Abstract reproduced from Chen T et al., JAMA Network Open (2023), under a CC BY 4.0 license, with punctuation lightly adapted. Plain-English summary by Womanhattan.
This summary was written with AI assistance and checked against the original paper. It is for learning, not medical advice. Talk with your care team before changing anything about your health or treatment.